							6.		953	ž)			Sheet _	_ <u>1</u> of	_1	
FORM PTO-1449			U.S. DEPARTMENT OF COMMERCE PATENT AND TRANSPORTED								ATTY, DOCKET NO.	SERIAL I	SERIAL NO.			
		PATENT AND TRANSMARK OFFICE							ICE	2026-4034	07/950,380					
INFORMATION DISCLOSURE CITATION									ΓΙΟΝ	APPLICANT Wilson, et al.						
(Use several sheets if necessa							cessa	isary)			FILING DATE September 22, 1992	GROUP 1205				
•	PATENT DOCUMENTS															
EXAMINER INITIAL			DOCUMENT NUMBER DATE								NAME	CLASS	FILING DATE CLASS SUBCLASS IF APPROPRIATE			
								52			CEAGG	Bebelins				
						ļ		<u> </u>		╁┈			盎;			
										<u> </u>			FEB			
•						-				 						
								<u> </u>	Y				R			
•										<u> </u>			- .			
													6			
		_							FOREIGN P	PATE	NT DOCUMENTS					
	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
_						Γ	1	I						YES	NO	
						_										
												ļ				
											,					
					(OTHE	R DO	CUMI	ENTS (Includir	ng Au	thor, Title, Date, Pertinent Papers, Etc.)					
1		1.							il of Taxol, an 991). –	Activ	ve Drug in the Treatment of Metastatic Brea	st Cancer"	, J. Natl. Can	cer Inst.,		
42		2.	Extr	a, J.M	., et a	ıl., "Pl	nase I '	Trial o	f Taxotere", P	Proc.	Am. Assoc. Cancer Res. Annu. Meet., 32,	205, (Marc	h 1991).			
	3. Schmid, S.M., et al., "IFN 6 Augmentation of Taxol Anticellular Effect: Comparison with Taxol/Cisplatin or Taxol/AMCF-7 Breast Carcinoma Cells", J. Interferon Res. 11 (Suppl. 1) S237 (1991). 4. Fojo, A.T., et al., "Expression of A Multidrug-Resistance Gene in Human Tumors and Tissues", Proc. Natl. Acad. Sci. 269, (January 1987).													mycin in		
0														SA 84, 26	55-	

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-FB-AB20 (also form PTO-1449)

Patent and Trademark Office - U.S. DEPARTMENT of COMMERCE